Entera Bio (ENTX) Cash from Operations (2021 - 2026)
Entera Bio (ENTX) recorded quarterly Cash from Operations of 3090000.0 in Q1 2026, down 68.58% on a QoQ basis from 1833000.0 in Q4 2025, and down 120.09% year-over-year from 15384255.32 in Q1 2025.
Entera Bio (ENTX) Cash from Operations (2021 - 2026) Analysis & Trends
Entera Bio has disclosed Cash from Operations across 6 years of filings, most recently posting 3090000.0 for Q1 2026.
- Quarterly Cash from Operations fell 120.09% year-over-year to 3090000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9056000.0 (down 42.39% YoY) and the FY2025 annual result came in at 7370000.0, down 8.1% from the prior year.
- Cash from Operations slipped to 3090000.0 in Q1 2026, from 1833000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1335000.0 in Q2 2024 and troughed at 4792000.0 in Q1 2022.
- A 5-year average of 2181588.24 and a median of 1862000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 66.42% — and 2026, when it slumped 120.09%.
- Tracing ENTX's Cash from Operations over 5 years: stood at 2011000.0 in 2022, then tumbled by 30.13% to 2617000.0 in 2023, then surged by 43.94% to 1467000.0 in 2024, then decreased by 24.95% to 1833000.0 in 2025, then plunged by 68.58% to 3090000.0 in 2026.
- Business Quant data shows ENTX's Cash from Operations at 3090000.0 in Q1 2026, 1833000.0 in Q4 2025, and 2502000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - | -3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.09 Mn |
| Mar 31, 2026 | -3.09 Mn |
| Dec 31, 2025 | -1.83 Mn |
| Dec 31, 2025 | -1.83 Mn |
| Sep 30, 2025 | -2.50 Mn |
| Sep 30, 2025 | -2.50 Mn |
| Jun 30, 2025 | -1.63 Mn |
| Jun 30, 2025 | -1.63 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Dec 31, 2024 | -1.47 Mn |
| Dec 31, 2024 | -1.47 Mn |
| Sep 30, 2024 | -2.15 Mn |
| Sep 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | -1.34 Mn |
| Jun 30, 2024 | -1.34 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Dec 31, 2023 | -2.62 Mn |
| Dec 31, 2023 | -2.62 Mn |